By: another FDAer
Purdue’s oxycontin is an absurdly and unjustifiably overpriced drug. Some oxycontin strengths go for ~$15 A PIECE, making purdue my LEAST favorite phara company. When oxycontin FINALLY goes off patent...
View ArticleBy: Sleeper
Well, Purdue is certainly betting big on Intermezzo… http://adage.com/article/news/intermezzo-rouses-drug-category-100-million-push/234014/
View ArticleBy: Sam R.Ph.
Ever since a great number of physicians became pain management specialist, class II conrolled drugs prescriptions have soar. The headlines in the news media indicate that the DEA is looking into...
View ArticleBy: AnnePME
Thanks Ed. Currently, I am having some problems getting my health insurer and their PBM to properly process and authorize a vital medication. This medication helps mitigate pain and prevents me from...
View ArticleBy: original industry insider
The worst of all possible worlds is when an inexperienced doctor uses homeopathic doses of narcotics for severe pain out of fear that the patient will become an addict. On the other hand there are many...
View ArticleBy: John@PGISelfDirected
I guess original industry insider’s two cents’ worth just summed it up. Nice post!
View ArticleBy: original industry insider
Sam, what would be the financial hit to your business if you quit dispensing narcotics altogether? My guess is that your business insurance costs would decline significantly, maybe offesetting the lost...
View ArticleBy: Former RPh
A place to start is to limit who can prescribe these type of meds. No General Practicioner, Dentist, Cardiologist, etc should be prescribing Oxycontin. I can’t think of any reason a Dentist should...
View ArticleBy: Pain Developer
Want to curb abuse? Take all of those schedule III and make them CII. Poof. Overnight change in abuse rates and a decrease in co-morbidities from APAP.
View ArticleBy: Pain Developer
Let’s also add that a federal law narcotic dosage requirements to 3-5 days worth of pills for non-chronic pain would go a long way to prevent over-prescribing.
View Article
